Exploiting the hallmarks of cancer

The Hallmarks of Cancer

2000 • 27,569 citations

Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene

1987 • 11,429 citations

Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2

2001 • 11,070 citations

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

2001 • 10,602 citations

Tumor Angiogenesis: Therapeutic Implications

1971 • 9,898 citations

A Gene-Expression Signature as a Predictor of Survival in Breast Cancer

2002 • 6,428 citations

Tumoricidal activity of tumor necrosis factor–related apoptosis–inducing ligand in vivo

1999 • 2,494 citations

Apoptosis

2002 • 2,190 citations

ON THE TREATMENT OF INOPERABLE CASES OF CARCINOMA OF THE MAMMA: SUGGESTIONS FOR A NEW METHOD OF TREATMENT, WITH ILLUSTRATIVE CASES.

1896 • 1,633 citations

ON THE TREATMENT OF INOPERABLE CASES OF CARCINOMA OF THE MAMMA: SUGGESTIONS FOR A NEW METHOD OF TREATMENT, WITH ILLUSTRATIVE CASES.1

1896 • 1,240 citations

Insulin-Like Growth Factors

1997 • 897 citations

Development of Matrix Metalloproteinase Inhibitors in Cancer Therapy

2001 • 788 citations

Cyclin E and Survival in Patients with Breast Cancer

2002 • 564 citations

WOODPECKERS' TONGUES

1976 • 553 citations

Estrogen activates telomerase.

1999 • 509 citations

Marimastat as First-Line Therapy for Patients With Unresectable Pancreatic Cancer: A Randomized Trial

2001 • 432 citations

Effects of cationic porphyrins as G-quadruplex interactive agents in human tumor cells.

1999 • 358 citations

The cell cycle inhibitor p27 is an independent prognostic marker in small (T1a,b) invasive breast carcinomas.

1997 • 354 citations

The Prognostic Significance of Altered Cyclin-Dependent Kinase Inhibitors in Human Cancer

1999 • 323 citations

Immunohistochemical distribution of type IV collagenase in normal, benign, and malignant breast tissue.

1990 • 323 citations

Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response.

2003 • 304 citations

M(r) 92,000 type IV collagenase is increased in plasma of patients with colon cancer and breast cancer.

1993 • 298 citations

P21-dependent G1arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228

2000 • 280 citations

Downregulation of telomerase reverse transcriptase mRNA expression by wild type p53 in human tumor cells

2000 • 257 citations

Breast Cancer

1992 • 249 citations

Randomized Phase III Trial of Marimastat Versus Placebo in Patients With Metastatic Breast Cancer Who Have Responding or Stable Disease After First-Line Chemotherapy: Eastern Cooperative Oncology Group Trial E2196

2004 • 249 citations

Anastozole (A) is superior to tamoxifen (T) in treatment of postmenopausal (PM) women with early breast cancer (EBC) - First results of the ATAC (Arimidex, tamoxifen, alone or in combination) trial (on behalf of the ATAC Trialists' Group)

2002 • 246 citations

Survivin expression and resistance to anticancer treatments: perspectives for new therapeutic interventions

2002 • 204 citations

Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424).

2002 • 194 citations

Effect of Matrix Metalloproteinase Inhibitor Batimastat on Breast Cancer Regrowth and Metastasis in Athymic Mice

1995 • 190 citations

Quantitation of hTERT gene expression in sporadic breast tumors with a real-time reverse transcription-polymerase chain reaction assay.

2000 • 185 citations

HER-2 amplification impedes the antiproliferative effects of hormone therapy in estrogen receptor-positive primary breast cancer.

2001 • 174 citations

Epidermal growth factor receptor vIII enhances tumorigenicity in human breast cancer.

2000 • 147 citations

Mammary tumors in mice conditionally mutant for Brca1 exhibit gross genomic instability and centrosome amplification yet display a recurring distribution of genomic imbalances that is similar to human breast cancer

2002 • 144 citations

ErbB (HER) receptors can abrogate antiestrogen action in human breast cancer by multiple signaling mechanisms.

2003 • 140 citations

Comparative analysis of the expression patterns of metalloproteinases and their inhibitors in breast neoplasia, sporadic colorectal neoplasia, pulmonary carcinomas and malignant non-Hodgkin's lymphomas in humans

1996 • 133 citations

Blockade of the epidermal growth factor receptor tyrosine kinase suppresses tumorigenesis in MMTV/Neu + MMTV/TGF-α bigenic mice

2000 • 128 citations

Phase I Clinical and Pharmacokinetic Study of Flavopiridol Administered as a Daily 1-Hour Infusion in Patients With Advanced Neoplasms

2002 • 126 citations

The GH–IGF-I axis and breast cancer

2003 • 123 citations

Phase I clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridol

2002 • 121 citations

Ribozyme cleavage of telomerase mRNA sensitizes breast epithelial cells to inhibitors of topoisomerase.

2001 • 117 citations

Progesterone regulates human telomerase reverse transcriptase gene expression via activation of mitogen-activated protein kinase signaling pathway.

2000 • 112 citations

Retinoic Acid Inhibition of Cell Cycle Progression in MCF-7 Human Breast Cancer Cells

1997 • 93 citations

Molecular and pharmacokinetic properties associated with the therapeutics of bcl-2 antisense oligonucleotide G3139 combined with free and liposomal doxorubicin.

2000 • 93 citations

Telomerase and breast cancer

2001 • 87 citations

Transforming growth factor alpha and mouse models of human breast cancer

2000 • 86 citations

Mammary gland specific hEGF receptor transgene expression induces neoplasia and inhibits differentiation

2000 • 80 citations

S-Phase Fraction and Urokinase Plasminogen Activator Are Better Markers for Distant Recurrences Than Nottingham Prognostic Index and Histologic Grade in a Prospective Study of Premenopausal Lymph Node–Negative Breast Cancer

2001 • 77 citations

Reduced telomere DNA content is correlated with genomic instability and metastasis in invasive human breast carcinoma

1999 • 76 citations

Clinical Utility of Urokinase-Type Plasminogen Activator and Plasminogen Activator Inhibitor—1 Determination in Primary Breast Cancer Tissue for Individualized Therapy Concepts

2002 • 65 citations

A randomized trial of tamoxifen alone or combined with octreotide in the treatment of women with metastatic breast carcinoma

1999 • 63 citations

Transgenic mice reveal roles for TGFalpha and EGF receptor in mammary gland development and neoplasia.

1997 • 60 citations

A randomized phase II pilot trial of adjuvant marimastat in patients with early-stage breast cancer

2002 • 59 citations

Cell-cycle dysregulation in breast cancer: breast cancer therapies targeting the cell cycle

2000 • 57 citations

The ATAC (Arimidex, Tamoxifen, Alone or in Combination) adjuvant breast cancer trial in postmenopausal (PM) women.

2001 • 55 citations

Restoration of estrogen responsiveness by blocking the HER-2/neu pathway

2002 • 50 citations

Telomerase activity in ductal carcinoma in situ of the breast

1999 • 45 citations

Assessment of genomic instability in breast cancer and uveal melanoma by random amplified polymorphic DNA analysis

2002 • 44 citations

Aberrant expression of cell‐cycle regulator cyclin D1 in breast cancer is related to chromosomal genomic instability

2002 • 42 citations

Telomerase activity and lymphovascular invasion in breast cancer

2000 • 41 citations

The Cyclin-dependent Kinase Inhibitor p21WAF1/Cip1 Is an Antiestrogen-regulated Inhibitor of Cdk4 in Human Breast Cancer Cells

2002 • 40 citations

Constitutional genomic instability with inversions, duplications, and amplifications in 9p23-24 in BRCA2 mutation carriers.

2001 • 40 citations

p21WAF1/CIP1 Expression in breast cancers: associations with p53 and outcome

2000 • 40 citations

Bcl-2 with loss of apoptosis allows accumulation of genetic alterations: A pathway to metastatic progression in human breast cancer

2000 • 40 citations

Mutant p53 and genomic instability in a transgenic mouse model of breast cancer

2000 • 39 citations

A unique form of proliferating cell nuclear antigen is present in malignant breast cells.

1998 • 37 citations

A randomized, multicenter prospective trial assessing long‐acting release octreotide pamoate plus tamoxifen as a first line therapy for advanced breast carcinoma

2002 • 36 citations

Human breast cancer cells contain an error-prone DNA replication apparatus.

1998 • 31 citations

Genomic instability and poor prognosis associated with abnormal TP53 in breast carcinomas. Molecular and immunohistochemical analysis

1997 • 29 citations

Tumor-Biological Factors Upa and PAI-1 as Stratification Criteria of a Multicenter Adjuvant Chemotherapy Trial in Node-Negative Breast Cancer

2000 • 28 citations

The antiestrogen ICI 182,780 inhibits proliferation of human breast cancer cells by interfering with multiple, sequential estrogen-regulated processes required for cell cycle completion

2000 • 23 citations

Octreotide as first-line treatment for women with metastatic breast cancer

1996 • 20 citations

Cyclin D1, Retinoblastoma, p53, and Her2/neu Protein Expression in Preinvasive Breast Pathologies: Correlation with Vascularity

2000 • 17 citations

Telomerase activity in microdissected human breast cancer tissues: association with p53, p21 and outcome

2002 • 16 citations

IGF‐1 Receptor as the Restriction Point of the Cell Cycle

1992 • 14 citations

Telomerase Inhibition by Induced Expression of Antisense RNA

1998 • 9 citations

Deleted Work

1955 • 0 citations